JEMPERLI was studied in the largest single-agent immunotherapy trial dataset in endometrial cancer, GARNET1,2

GARNET was a global, multicenter, multiple cohort, open-label study1

Patient Population1

  • Recurrent or advanced endometrial cancer that had progressed on or following treatment with a platinum-containing regimen
  • Tumors that were mismatch repair deficient (dMMR) as determined by IHC testing. The dMMR tumor status was retrospectively confirmed using the VENTANA MMR RxDx Panel assay
  • Efficacy analysis included 141 patients, and safety analysis included 150 patients

Patients received: JEMPERLI 500 mg IV every 3 weeks for 4 doses, followed by 1000 mg IV every 6 weeks1*

Primary Efficacy Endpoints1†

  • Overall response rate (ORR)
  • Duration of response (DOR)

*Treatment continued until disease progression or unacceptable toxicity.1

As assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.1

GARNET inclusion and exclusion criteria table

89% of patients had received prior anticancer surgery and 71% had received prior anticancer radiotherapy. Approximately 37% of patients had 2 lines or more of prior anticancer treatment in total.1

IHC=immunohistochemistry; IV=intravenous; PD-1=programmed death receptor 1; PD-L1=programmed death ligand 1.

GARNET Cohort A1: Patient baseline characteristics1,3

Efficacy population baseline characteristics (n=141)1

Of the 150 patients in the study with dMMR endometrial cancer who received JEMPERLI, 141 were included in the efficacy analysis.

GARNET cohort A1 patient baseline characteristics infographic

Other includes dedifferentiated, endometrial adenocarcinoma, endometrial adenocarcinoma NOS, endometrial neuroendocrine carcinoma, high-grade uterine carcinoma, undifferentiated clear cell carcinoma.

ECOG=Eastern Cooperative Oncology Group; NOS=not otherwise specified.

GARNET ECOG performance status and race data infographic

Overall Response Rate

JEMPERLI established efficacy over ≥2 years of follow-up1

Proven efficacy at median follow-up of 27.9 months1§

The largest single-agent immunotherapy trial data set in dMMR recurrent or advanced endometrial cancer (n=141)1,2

GARNET Cohort A1 overall response rate graphic
  • Overall response rates in patients based on lines of prior therapy3:
    • 43.8% (n=39) in those who received 1 prior line (95% CI: [33.3, 54.7])
    • 48.1% (n=25) in those who received ≥2 prior lines (95% CI: [34.0, 62.4])
    • Due to small sample sizes and wide confidence intervals, results should be interpreted with caution
  • Responses to JEMPERLI were seen across histologies, including serous, Grade 3 endometrioid, mixed, unspecified, clear cell, undifferentiated, and squamous carcinoma3

§Measured from time of first response.

CI=confidence interval; CR=complete response; PR=partial response.

NCCN Guidelines recommend dostarlimab-gxly (JEMPERLI) as a treatment option for patients with dMMR recurrent or advanced endometrial carcinoma that has progressed on or following prior treatment with a platinum-containing regimen4

All recommendations are category 2A unless otherwise indicated.

Category 2A - Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Duration of Response

JEMPERLI has shown durable response over ≥2 years of follow-up1

At 27.9 months median follow-up,II median duration of response was not reached

85.9% of responding patients demonstrated a duration of response ≥1 yearII

54.7% of responding patients demonstrated a duration of response >2 yearsII

IIMeasured from time of first response.

Treatment duration of responders3

GARNET Cohort A1 duration of response graph
Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety profile
from the GARNET trial

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Learn about

Icon: JEMPERLI (dostarlimab-gxly) Support

Learn about support for
JEMPERLI at every step